Valneva's 2024 Guidance: Expects Product Sales Of €150M-€180M, Reflecting Continued Revenue Growth For Proprietary Products And IXCHIQ®'S Launch-Year Sales
Portfolio Pulse from Benzinga Newsdesk
Valneva expects 2024 product sales to range between €150M-€180M, driven by growth in proprietary products and IXCHIQ® launch-year sales, despite supply constraints. Other income is anticipated to be €95M-€105M, including a €95M PRV sale. R&D expenses are projected between €65M-€90M.
February 15, 2024 | 6:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva projects 2024 sales between €150M-€180M, highlighting growth from proprietary products and IXCHIQ® despite some supply constraints. Other income, including a €95M PRV sale, expected to be €95M-€105M. R&D expenses estimated at €65M-€90M.
Valneva's guidance for 2024 indicates a positive outlook with expected growth in product sales, particularly from its proprietary products and the launch of IXCHIQ®. The sale of a PRV for €95M also contributes to a strong other income projection. Despite the anticipated supply constraints, the overall positive guidance suggests a likely positive impact on Valneva's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100